Application of proteomics to cancer early detection

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 423-428

  Hanash, Samir ^a   Taguchi, Ayumu ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

early cancer detection; Proteomics

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 19-9 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN 1; MYC PROTEIN; NY ESO 1 ANTIGEN; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

BIOINFORMATICS; BLOOD ANALYSIS; CANCER CELL; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CANCER TISSUE; EARLY DIAGNOSIS; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SYMPTOM;

ANIMALS; DISEASE MODELS, ANIMAL; EARLY DETECTION OF CANCER; HUMANS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 83755174132     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182383cab     Document Type: Review

References (64)

1. Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4:365-374.
2. Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4:375-383.
3. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila). 2011;4:303-306.
4. Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Cancer. [published online ahead of print June 29, 2011] doi:10.1002/cncr.26241.
5. Buchen L. Cancer: missing the mark. Nature. 2011;471:428-432.
6. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588-599.
7. Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005; 23:378-391. (Pubitemid 46206885)
8. Seeff LC, Manninen DL, Dong FB, et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology. 2004;127:1661-1669. (Pubitemid 39575844)
9. Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physician counseling. Prev Med. 2005;41:23-29. (Pubitemid 40755060)
10. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen InternMed. 2005;20:989-995. (Pubitemid 41726651)
11. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365:395-409.
12. Nawa T, Nakagawa T, Kusano S, et al. Lung cancer screening using lowdose spiral CT: results of baseline and 1-year follow-up studies. Chest. 2002;122:15-20. (Pubitemid 34754137)
13. McWilliams AM, Mayo JR, Ahn MI, et al. Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy. J Thorac Oncol. 2006;1:61-68. (Pubitemid 47164022)
14. Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat Rev Cancer. 2010;10:652-660.
15. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 2008;41:615-625.
16. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med. 2007;13:249-255. (Pubitemid 46847287)
17. Farlow EC, Vercillo MS, Coon JS, et al. A multi-analyte serum test for the detection of nonYsmall cell lung cancer. Br J Cancer. 2010;103: 1221-1228.
18. Faca VM, Hanash SM. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 2009;69:728-730.
19. Zeng Z, Hincapie M, Pitteri SJ, et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem. 2011;83: 4845-4854.
20. Monetti M, Nagaraj N, Sharma K, et al. Large-scale phosphosite quantification in tissues by a spike-in SILAC method. Nat Methods. 2011;8: 655-658.
21. Thakur SS, Geiger T, Chatterjee B, et al. Deep and highly sensitive proteome coverage by LC-MS/MS without prefractionation. Mol Cell Proteomics. 2011;10:M110 003699.
22. Zhang Q, Faca V, Hanash S. Mining the plasma proteome for disease applications across seven logs of protein abundance. J Proteome Res. 2011;10:46-50.
23. Kirby R, Cho EJ, Gehrke B, et al. Aptamer-based sensor arrays for the detection and quantitation of proteins. Anal Chem. 2004;76: 4066-4075. (Pubitemid 38943679)
24. Yee J, Sadar MD, Sin DD, et al. Connective tissueYactivating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol. 2009;27:2787-2792.
25. Taylor AD, Hancock WS, Hincapie M, et al. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med. 2009;1:57.
26. Wang H, Wong CH, Chin A, et al. Integrated mass spectrometry based analysis of plasma glycoproteins and their glycan modifications. Nat Protocols. 2011;6:253-269.
27. Yue T, Goldstein IJ, Hollingsworth MA, et al. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibodyYlectin sandwich arrays. Mol Cell Proteomics. 2009;8:1697-1707.
28. Heo SH, Lee SJ, Ryoo HM, et al. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics. 2007;74292-4302.
29. Li B, An HJ, Kirmiz C, et al. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res. 2008;7:3776-3788.
30. Faca VM, Song KS,Wang H, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008;5:e123.
31. Taguchi A, Politi K, Pitteri S, et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011;20:289-299.
32. Tan HT, Low J, Lim SG, et al. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880-6904.
33. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007;18:868-873. (Pubitemid 47054083)
34. Chang WJ,Wu LL, Cao F, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res. 2011;17:5715-5724.
35. Brichory F, Beer D, Le Naour F, et al. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61:7908-7912. (Pubitemid 33049381)
36. Brichory F, Misek D, Yim A, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2002;98:9824-9829. (Pubitemid 32769388)
37. Pereira-Faca SR, Kuick R, Puravs E, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007;67:12000-12006.
38. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26:5060-5066.
39. Bassani-Sternberg M, Barnea E, Beer I, et al. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci U S A. 2010;107:18769-18776.
40. Wolpin BM, Wei EK, Ng K, et al. Prediagnostic plasma folate and the risk of death in patients with colorectal cancer. J Clin Oncol. 2008; 26:3222-3228.
41. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:799-810.
42. Douglas JB, Silverman DT, Pollak MN, et al. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2010;19:2298-2306.
43. Pitteri SJ, Amon LM, Busald Buson T, et al. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users. Cancer Res. 2010;70: 8598-8606.
44. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100:1432-1438.
45. Rajagopal MU, Hathout Y, MacDonald TJ, et al. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: a pediatric brain tumor consortium study. Proteomics. 2011;11:935-943.
46. Roy S, Josephson SA, Fridlyand J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008; 26:96-105.
47. Jou YJ, Lin CD, Lai CH, et al. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010;681:41-48.
48. de Jong EP, Xie H, Onsongo G, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing premalignant and malignant oral lesions. PloS One. 2010;5:e11148.
49. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14:6246-6252.
50. Dowling P, Wormald R, Meleady P, et al. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J Proteomics. 2008;71:168-175. (Pubitemid 351915861)
51. Pawlik TM, Hawke DH, Liu Y, et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006;6:68.
52. Wang CL, Wang CI, Liao PC, et al. Discovery of retinoblastomaassociated binding protein 46 as a novel prognostic marker for distant metastasis in nonYsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res. 2009;8:4428-4440.
53. Pernemalm M, De Petris L, Eriksson H, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics. 2009;9:3414-3424.
54. Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, et al. On the identification of biomarkers for nonYsmall cell lung cancer in serum and pleural effusion. J Proteomics. 2010;73:1511-1522.
55. Oumeraci T, Schmidt B, Wolf T, et al. Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology. Lung Cancer. 2011;72:136-138.
56. Chen R, Pan S, Duan X, et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer. 2010;9:149.
57. Elschenbroich S, Ignatchenko V, Clarke B, et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res. 2011;10: 2286-2299.
58. Amon LM, Law W, Fitzgibbon MP, et al. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PloS One. 2010;5:e11137.
59. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241.
60. Chen YT, Chen CL, Chen HW, et al. Discovery of novel bladder cancer biomarkers by comparative urine proteomics using iTRAQ technology. J Proteome Res. 2010;9:5803-5815.
61. Feldman AS, Banyard J,Wu CL, et al. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin Cancer Res. 2009;15:1024-1031.
62. Kreunin P, Zhao J, Rosser C, et al. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res. 2007;6:2631-2639. (Pubitemid 47122358)
63. Theodorescu D, Schiffer E, Bauer HW, et al. Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008;2: 556-570. (Pubitemid 351566263)
64. Ye B, Skates S, Mok SC, et al. Proteomic-based discovery and characterization of glycosylated eosinophilYderived neurotoxin and COOHterminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 2006;12:432-441. (Pubitemid 43166132)